Trauma-focused therapies to reduce post-traumatic stress symptoms Mental and Behavioural Disorders
Conditions
Interventions
The participant will be offered 24 sessions of therapy, over a maximum 9-month time period by a Health and Care Professionals Council (HCPC) registered Clinical Psychologist or therapist with speciali
Shapiro et al., 2018) or an adapted version of trauma focused CBT for PTSD, based on Ehlers and Clark’s (2000) model.
Participants will continue to receive treatment as usual throughout the therapy
Sponsors
University of Manchester
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. A probable PTSD/ complex PTSD according to the following thresholds: 1.1. At least one trauma event on the TALE 1.2. A probable diagnosis of PTSD or Complex PTSD as defined by the standard diagnostic algorithm for the ITQ (Cloitre et al., 2018) 1.3. A score of 31 or more on the PCL-5 2. Aged 60 years and above 3. Score of 22+ on the MOCA (Nasreddine et al., 2004). 4. Supported by an adult or an older adult community mental health team. 5. Capacity and willingness to provide informed consent.
Exclusion criteria
Exclusion criteria: 1. Currently in a mental health crisis and/or actively suicidal 2. Insufficient English-language skills to comprehend the assessment and therapy content.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility of the adapted trauma focused therapy intervention using the following metrics: 1.Individuals approached regarding the study measured using total numbers at the end of the recruitment period. 2.Individuals approached who are eligible and consent to take part in the study measured using total numbers at the end of the recruitment period. 3.Individuals approached who are eligible and do not take part in the study measured using total numbers at the end of the recruitment period. 4.Therapy sessions attended measured using total numbers at the end of the therapy sessions. 5.Participants who drop-out and at which point in the therapy measured using total numbers at the point of drop-out. 6.Adverse Events and Serious Adverse Events measured using total numbers at the end of the follow-up period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Any preliminary potential clinical benefits will be determined using the following outcome measures; changes in outcome measure scores from first baseline to 9 month follow-up will be calculated. The suitability of outcome measures will also be measured (determined by % completion). 1. The International Trauma Questionnaire (ITQ; Cloitre et al., 2018), 2. The Post Traumatic Stress Checklist for DSM-5 (PCL-5; Wheathers et al., 2013), 3. the Dissociative Subtype of PTSD Scale (DSPS; Wolf et al., 2017), 4. The 9-item version of the Patient Health Questionnaire (PHQ-9; Kroenke et al, 2001) 5. The Altman Self-Rating Mania Scale (Altman et al., 1997) 6. 7-item version of the General Anxiety Disorder scale (GAD-7; Spitzer et al., 2006) 7. The Community Assessment of Psychic Experiences- Positive Scale (CAPE-15; Capra et al., 2017) 8. The Questionnaire about the Process of Recovery (QPR; Neil et al., 2007) Potential clinical benefits will also be determined by plotting the weekly sessional scores to examine treatment effects in more detail. After the end of therapy, participants will be asked to participate in an optional semi-structured interview that will aim to explore individuals’ experiences of receiving the trauma-focused intervention in more detail. | — |
Countries
England, United Kingdom
Contacts
Public ContactElizabeth Tyler
Outcome results
None listed